According to Biotechnology and Bioengineering:
A variety of approaches has been employed to address the problem of reduced capacity due to virus spiking, including implementing changes in the order of spike addition (i.e., RUNspike), the use of bacteriophages for research studies, and now the implementation of more highly purified mammalian viruses. While the traditional spiking study adds virus at the beginning of the filtration process, the RUNspike method was developed to compensate for any deleterious effects from the spike by adding virus at the end of the filtration run after the desired throughput had been
achieved (Khan et al., 2009; Parrella et al., 2009).
This article goes more in depth on systematically prepared and analyzed different grades of parvovirus with different purity levels and compared their performance profiles on Viresolve1 Pro parvovirus filters using four different molecule. Read it here.
This year at Biopharmaceutical Development and Production Event, this topic will be examined in depth with presentations such as Physical Inactivation of Small Non-enveloped Viruses presented by RMC Pharmaceutical Solutions, High Titer and Highly Purified Virus Stocks Preparations in
Virus Clearance Studies presented by Charles River Biopharmaceutical Services and more. If you'd like to find out more about this event taking place February 25-March 1, 2013, download the agenda. If you'd like to join us in Huntington Beach, California, register today and mention code BDP13JP to save 20% off the standard rate!*
*This rate only applies if you have not registered for the event.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment